stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Revenue
Genmab A/S Sponsored ADR's revenue for fiscal 2025 was $3.7B, up 19.2% from $3.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.1B. Over the past ten years it has ranged from $257.6M (fiscal 2016) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Genmab A/S Sponsored ADR ranks 8th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.7B | 19.19% |
| FY2024 | $3.1B | 30.48% |
| FY2023 | $2.4B | 15.74% |
| FY2022 | $2.1B | 53.14% |
| FY2021 | $1.3B | (12.88%) |
| FY2020 | $1.5B | 92.58% |
| FY2019 | $804.4M | 67.86% |
| FY2018 | $479.2M | 25.82% |
| FY2017 | $380.8M | 47.85% |
| FY2016 | $257.6M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.2B | 28.91% |
| Mar 2026 | $896.0M | (15.31%) |
| Dec 2025 | $1.1B | 3.52% |
| Sep 2025 | $1.0B | 10.49% |
| 27 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| GMAB Genmab A/S Sponsored ADR | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| INSM Insmed, Inc. compare | $1.5B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GMAB
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement